Support provided by Revolution Medicines. Content independently published by OncLive. This presentation describes a study evaluating daraxonrasib as an initial treatment for metastatic pancreatic cancer driven by RAS mutations. The therapy showed promising tumor response and disease control with a manageable safety profile, suggesting potential improvement over existing chemotherapy options. These findings support further investigation in larger clinical trials.
